Cidara Therapeutics: All Stars Aligning In Favor Of CD388

This is my 4th coverage of Cidara Therapeutics (NASDAQ: CDTX ). At the time of writing, CDTX is trading at around +90% since my last coverage. CDTX has always been a long-term investment for me as explained in prior articles, but the Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole ...